Evaluate your walking ability
Multiple sclerosis (MS) affects people’s walking differently and it’s important to let your healthcare professional know about symptoms you’re experiencing.
To help you evaluate your current walking ability, we have developed a personalized tool that you can bring with you to your next doctor’s appointment. This Self-Assessment is based on the 12-Item Multiple Sclerosis Walking Scale (or MSWS-12)—a scale that can be used by people with MS to rate the impact of MS on their walking ability.
Start assessing your walking now
Or, if you are in a hurry...
PDF | 176kb | 7 pages
About PDF Files
PDF stands for "Portable Document Format." PDF files require Adobe Acrobat Reader, which can be downloaded free from the Adobe website at www.adobe.com.
Important notice: Acorda respects your right to have personal and medical information kept confidential. Acorda
cannot access this information.
THIS SELF-ASSESSMENT IS INTENDED FOR INFORMATIONAL PURPOSES ONLY. IT IS NOT A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE, DIAGNOSIS OR TREATMENT.
AMPYRA® (dalfampridine) is indicated as a treatment to improve walking in patients with MS. AMPYRA improved walking in significantly more people with MS than placebo (sugar pill) in two clinical trials (34.8% vs. 8.3% and 42.9% vs. 9.3%). This was demonstrated by an increase in walking speed. In the clinical studies, people who walked faster, regardless of treatment, also reported improvements in their walking-related activities.† This was shown using the 12-Item Multiple Sclerosis Walking Scale (or MSWS-12).
Not everyone responds to AMPYRA. Individual results may vary.
†A drug/placebo difference was not established for this outcome measure.